Investors Sell Shares of Johnson & Johnson (JNJ) on Strength (JNJ)

Traders sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading on Monday. $98.18 million flowed into the stock on the tick-up and $209.64 million flowed out of the stock on the tick-down, for a money net flow of $111.46 million out of the stock. Of all stocks tracked, Johnson & Johnson had the 7th highest net out-flow for the day. Johnson & Johnson traded up $0.54 for the day and closed at $136.52

A number of analysts recently weighed in on the stock. Zacks Investment Research reaffirmed a “sell” rating on shares of Johnson & Johnson in a research report on Monday, December 31st. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 2nd. Barclays reaffirmed an “equal weight” rating and set a $135.00 price target (down from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Wells Fargo & Co reaffirmed an “outperform” rating and set a $152.00 price target (down from $162.00) on shares of Johnson & Johnson in a research report on Monday, January 14th. Finally, Citigroup upped their price target on shares of Johnson & Johnson from $139.00 to $147.00 and gave the stock a “neutral” rating in a research report on Monday, February 25th. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $143.58.

The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.20 and a current ratio of 1.47. The stock has a market cap of $362.76 billion, a price-to-earnings ratio of 16.69, a PEG ratio of 2.07 and a beta of 0.68.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, January 22nd. The company reported $1.97 earnings per share for the quarter, beating analysts’ consensus estimates of $1.95 by $0.02. The company had revenue of $20.39 billion during the quarter, compared to analysts’ expectations of $20.27 billion. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The firm’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.74 EPS. On average, analysts anticipate that Johnson & Johnson will post 8.58 EPS for the current year.

Johnson & Johnson announced that its Board of Directors has initiated a share repurchase plan on Monday, December 17th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 1.5% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Several institutional investors have recently modified their holdings of the company. Fundsmith Equity Fund L.P. acquired a new stake in Johnson & Johnson during the second quarter worth about $552,762,000. Peoples Financial Services CORP. raised its stake in Johnson & Johnson by 20.4% during the third quarter. Peoples Financial Services CORP. now owns 30,668 shares of the company’s stock worth $4,237,000 after acquiring an additional 5,190 shares during the period. Meeder Asset Management Inc. raised its stake in Johnson & Johnson by 29.1% during the fourth quarter. Meeder Asset Management Inc. now owns 98,256 shares of the company’s stock worth $12,679,000 after acquiring an additional 22,157 shares during the period. QUANTRES ASSET MANAGEMENT Ltd acquired a new stake in Johnson & Johnson during the third quarter worth about $829,000. Finally, Foundation Resource Management Inc. acquired a new stake in Johnson & Johnson during the third quarter worth about $208,000. Institutional investors and hedge funds own 67.29% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first reported by WKRB News and is the property of of WKRB News. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.wkrb13.com/2019/04/16/investors-sell-shares-of-johnson-johnson-jnj-on-strength-jnj.html.

About Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Do investors pay a separate front-end load every time they buy additional shares?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.